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INTRODUCTION 
 
 
 A prevalence study of systemic lupus erythematosus (SLE) in India showed a 
crude incidence rate of 4 per 100,000 population per year1. Lupus nephritis occurs in 
about half of SLE patients (range: 35%-73%) in India 2-7. Most patients with SLE do not 
present initially with renal disease1; only 25% of patients have this as their initial 
presenting feature. In 5% of these cases, usually in men older than 40 years, it can be 
several years before other lupus criteria or serological abnormalities develop8. 
 Although the survival of SLE patients have improved in the west with modern  
 
treatment to the tune of 80% at 10 years after diagnosis9, among Indians the figures are  
 
not so good (50%-60% survival at 10 years) as shown by Murali et al in a study of 98  
 
patients between 1981 and 199310,11. Renal involvement in SLE is a therapeutic  
 
challenge for all involved in the care of SLE, since early intervention can dramatically  
 
change the disease course. Thirty or more years ago, few patients with severe grade IV  
 
nephritis survived more than a year or two, and half of those with less severe form  
 
of nephritis used to die within 5 years12. After the introduction of Cyclophosphamide  
 
into the therapeutic armamentarium of lupus nephritis 20 years later, renal involvement 
no longer affects the survival rates of these patients13. However, long-term treatment with 
cyclophosphamide for patients with proliferative lupus nephritis is associated with 
adverse effects, including an increased risk of infection (10–18% per year) 14. Cumulative 
doses of cyclophosphamide over 9 g, particularly in women over the age of 32 years, are 
associated with ovarian failure15, 16. The aim of treatment therefore, is to induce and 
maintain remission of active nephritis with minimum toxicity. A major advance in 
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achieving the goal of identifying new therapies for the treatment of severe lupus nephritis 
occurred in 2000, with the report by Chan et al. of the first prospective controlled study 
comparing the efficacy and toxicity of Mycophenolate Mofetil (MMF) to oral 
Cyclophosphamide in patients with diffuse proliferative lupus nephritis 17. Also for 
maintenance therapy in lupus nephritis MMF seems to be a good alternative to 
azathioprine18. 
Mycophenolate mofetil (MMF) has become the most frequently used 
immunosuppressive drug in kidney transplant recipients. Initially, in patients with lupus 
nephritis MMF doses of up to 2 g daily were used. Subsequent dosing regimens started 
with 1 g MMF/day and titrated on a weekly basis up to a maximum of 3 g/day19. It is 
questionable whether standard dose therapy is the best way to treat a patient, given the 
large inter-individual variability in pharmacokinetics20. Since patients with autoimmune 
diseases are regularly treated with only one or two immunosuppressive drugs, an 
adequate Mycophenolic Acid (MPA) exposure may be even more important compared to 
renal transplant recipients receiving multiple immunosuppressive drugs. Also, in patients 
treated for autoimmune diseases MPA has highly variable pharmacokinetics, and dose is 
a poor predictor for MPA exposure 21. If in patients with autoimmune diseases MPA 
exposure can be shown to correlate with either efficacy or toxicity, then therapeutic drug 
monitoring could contribute to optimum patient care. 
 Hence we undertook to study the outcomes of exposure controlled MPA in 
proliferative lupus nephritis patients. 
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AIM 
 
  
 
To evaluate the Outcomes of Exposure-controlled Mycophenolic Acid as Induction and 
Maintenance therapy in Class III and IV Lupus Nephritis. 
 
 
 
 
 
 
OBJECTIVES 
 
 
1. To study the effect of Exposure-controlled Mycophenolic Acid on Inducing and Maintaining 
remission in Class III and Class IV Lupus Nephritis patients. 
 
2. To study the side effect profile and complications of Mycophenolic Acid therapy in Lupus 
Nephritis 
 
. 
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LITERATURE REVIEW 
 
Epidemiology 
A prevalence study in India (carried out in a rural population near Delhi) by 
Malaviya et al published in 1993 surveyed a population of 91,888 and found a point 
prevalence of 3 per 100,000 (95%CI= 0-6.86 per 100,000)22. This is a much lower figure 
than reported from the west (varying from 12.5 per100, 000 adults in England 23 to 39 per 
100,000 in Finland 24 and 124 per 100,000 in USA)25. However, a fair number of cases of 
SLE are encountered in any large hospital in India. The Copcord Bhigwan study (an 
ongoing, prospective population study from Pune) found a crude incidence rate of 1 per 
25,000 person years i.e. 4 per 100,000 population per year1. 
Among children, SLE occurs three times more commonly in females than in 
males. In the 60% of SLE patients who experience onset of their disease between puberty 
and the fourth decade of life the female to male ratio is 9:1. Thereafter, the female 
preponderance again falls to that observed in prepubescent26. 
The ethnic group at greatest risk is African Caribbean blacks. The annual 
incidence of SLE ranges from 6 to 35 new cases per 100,000 population in relatively low-
risk to high-risk groups26. 
Renal involvement in systemic lupus erythematosus (SLE) is a common disease 
manifestation and a strong predictor of poor outcome. The prevalence of renal disease in 
eight large cohort studies consisting of 2649 SLE patients varied from 31 to 65%9. A 
recent study analyzed the annual incidence of nephritis in 384 lupus patients followed at 
the Johns Hopkins Medical Center from 1992-94. The one year incidence of acute renal 
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disease was 10%27. Lupus nephritis occurs in about half of SLE patients (range 35%-
73%) in India1. 
 In a recent retrospective study, male sex, young age (<33years), and non-
European ancestry were found to be determinants of earlier renal involvement in SLE 
patients13. 
Etiology 
The etiology of SLE remains unknown. A genetic predisposition, sex hormones, 
and environmental trigger(s) likely result in the disordered immune response that typifies 
the disease26. 
HLA antigens have been associated with an increased risk of developing nephritis 
and the HLA-DR2 and HLA-B8 are more associated with the development of lupus renal 
disease 28- 30. Polymorphisms of Fc receptors for IgG (FcgammaR) were recently 
identified as a risk factor, implicating defective handling of circulating immune 
complexes in the development of renal disease31. The role for heredity is further 
supported by the concordance for this illness among monozygotic twins. The polygenic 
nature, however, of this genetic predisposition as well as the contribution of 
environmental factors is suggested by the only moderate concordance rate which is 
reported to be between 25 and 60%26. 
Immunopathogenesis of lupus nephritis 
 There are at least three potentially overlapping, immuno-pathogenic mechanisms 
supported by experimental data. First, circulating immune complexes consisting chiefly 
of DNA and anti-DNA are deposited in the kidney. Resulting complement activation and 
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chemotaxis of neutrophils leads to a local inflammatory process. Accumulating data 
suggest that Nucleosomes are the target and mediators of antibody-related glomerular 
immune-complex deposition32. The nucleosome is the fundamental unit of chromatin 
released by internucleosomal cleavage by endonucleases activated during cell apoptosis. 
It consists of a core composed of an octamer of two copies each of Histones H2A, H2B, 
H3 and H4, around which is wrapped a stretch of helical DNA, approximately 150bp in 
length32 (figure 1). Adjacent nucleosome particles are linked like beads on a string by 
histone-free linker DNA of about 60bp in length, and a molecule of histone H1 is located 
at the point where DNA enters and exits the nucleosome. Antibodies reactive to 
nucleosomes have been detected both in patients with lupus and murine models even 
prior to the development of anti-dsDNA and anti-histone antibodies32. These antibodies 
are IgG in isotype and usually are of IgG2a and IgG2b in subclass consistent with a T-
cell mediated antigen driven response32. 
Second, in situ formation of antigen and antibody complexes may similarly lead to 
complement activation and leucocyte-mediated injury. Third, antibodies against specific 
cellular targets may produce renal injury (figure 2). For example, antibodies, such as anti-
ribosomal P, may bind to cytoplasmic antigens that have been translocated to the cell 
membrane with subsequent penetration and disruption of cellular function.  
An additional mechanism is observed in SLE patients with the antiphospholipid 
antibody syndrome. Glomerular thrombosis can result from the hypercoagulability that 
accompanies antibodies directed against negatively charged phospholipid-protein 
complexes (e.g. biologic false positive VDRL, anticardiolipin antibodies, and lupus 
anticoagulant)32. 
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Presenting Signs and Symptoms  
 80% of patients with SLE present with involvement of the skin or joints.  
 
However, patients may present with fever accompanied by single organ involvement,  
 
such as inflammatory serositis, glomerulonephritis, neuropsychiatric disturbance or  
 
hematological disorder (i.e. autoimmune hemolytic anemia or thrombocytopenia). Rarely,  
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patients present with severe, generalized acute lupus crisis with multiorgan  
 
involvement 26. 
  
Clinical features reported by workers from different parts of India show some  
 
interesting regional variations2-7. Raynaud’s phenomenon is conspicuous by its  
 
absence in patient from southern India where lymphadenopathy tends to be a presenting  
 
feature more often2-7. Low frequency of neuropsychiatric manifestations at onset in  
 
northern India emerges as another significant difference. When patients are followed up  
 
for several years, significant differences can still be made out. These include lower  
 
frequency of photosensitivity and neuropsychiatric manifestations in western India, lower  
 
frequency of nephritis in central India in comparison to other parts of the country. But  
 
these studies are hospital based studies and hence may not reflect the true prevalence in  
 
the general population2-7. 
 
Diagnosis Of SLE 
 
 The American College of Rheumatology has a criteria for the classification of  
 
patients as  having SLE33. If a patient has, at any time in his or her medical history, 4  
 
of the 11 criteria listed, the diagnosis of SLE can be made with about 95%  
 
specificity and 85% sensitivity. These criteria are actually meant for epidemiological  
 
purposes (to ensure that SLE patients reported in the literature do in fact have the disease)  
 
and not for bedside diagnosis of an individual patient. The diagnosis of  SLE is based on  
 
clinical judgement. SLE can be suspected whenever 2 or more organ systems listed in  
 
ARA criteria are involved. Thus, a lady with nephritis and presence of ANA and anti- 
 
dSDNA meets only 3 criteria but can be treated as “Probable SLE”1. 
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Evaluation of disease activity and severity 
 
A number of validated indices are available for quantifying disease activity. The 
more popular indices include BILAG 34, SLEDAI 35, SLAM 36 and LAI 37. These help  
in formulating the overall treatment plan and assessment of prognosis. The details of  
 
SLEDAI activity index are shown in Annexure A. A valid measure of damage in patients 
with lupus is the SLICC/ ACR Damage Index (DI)38. 
Laboratory Procedures  
 
In 90-95% of patients with SLE the serum ANA will be positive typically with a  
 
speckled, diffuse, or peripheral pattern26. When the ANA is negative but the diagnosis is  
 
still strongly suspected a test for anti-Ro (SS-A) and anti-La (SS-B) antibodies can be 
used to identify the rare patient with ANA negative, Ro lupus. Additionally, a total 
hemolytic complement or CH50 can be helpful. A CH50 of zero is consistent with the 
unusual patient who has a homozygous early complement component deficiency (e.g. 
C1q, C2, C4), is at risk for developing a SLE-like illness, but is ANA negative26. 30-70% 
of patients with SLE will be anti-DNA positive. 30% of patients with SLE will be anti-
Sm positive. The presence of anti-double stranded DNA antibodies and 
hypocomplementemia strongly suggests the diagnosis of lupus and identifies the patient 
at increase risk for glomerulonephritis26. 
In patients with a history of recurrent thrombosis or recurrent fetal wastage, the 
presence of the antiphopholipid antibody syndrome is evaluated by a VDRL, PTT, 
sensitive assay for lupus anticoagulant such as the dilute Russell viper venom time, and  
anti-cardiolipin antibodies26. 
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Assessment of Renal Disease 
 
Assessment of urine and renal function- Urinary abnormalities of microscopic 
haematuria, proteinuria or pyuria (persistent white cells not due to infection) are usually 
the first indication of nephritis. It is essential that all patients with known SLE have 
regular urinalysis, even when extra-renal disease is thought to be controlled or minimal. 
Normal-range serum creatinine does not indicate normal renal function, particularly in 
patients with SLE, and calculation of creatinine clearance is advised.  
 
 
 
The Cockcroft–Gault formula can overestimate GFR, particularly in patients with 
impaired renal function. In these patients the MDRD equation, which was derived from 
the Modification of Diet in Renal Disease Study Group data, is recommended39. The 
advantages of this method are that no weight and height measurements are required but 
that ethnicity, which is an important factor in the development of end-stage renal disease 
(ESRD), is taken into account. 
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Newer methods such as measurement of serum cystatin C are being introduced and have 
been found to be a more sensitive marker for changes in glomerular filtration rate (GFR) 
than serum creatinine40. 
Assessment by renal biopsy- Although clinicians vary in their opinion, the strongest 
argument for a renal biopsy is likelihood that the pathologic findings will influence 
initiation, selection or discontinuation of therapeutic agents. In determining the role of 
renal biopsy in lupus renal disease several points are relevant. Transitions from one WHO 
Classification to another is not uncommon and occurs in as many as 20% of the patients, 
especially Class III. Although it is possible to infer the WHO class of renal disease by 
evaluating the urinalysis, 24 hour urine protein excretion, and serologies, this is not 
inviolate. There is data correlating WHO Classification and National Institute of Health 
activity and chronicity indices with prognosis and these can be discerned reliably only by 
biopsy. Another consideration is that membranous lupus nephritis has a different 
prognosis and treatment than proliferative disease41.  
A renal biopsy may be indicated when the clinical findings are indeterminate and 
objective evidence of active lupus nephritis is required prior to initiating treatment. More 
commonly, a biopsy may be required to determine whether aggressive (i.e. cytotoxic) 
therapy is warranted. Finally, in the setting of rising serum creatinine and loss of renal 
function, a biopsy may help distinguish a patient with a high activity but low to moderate 
chronicity index, an excellent candidate for therapy, from a patient with moderate to high 
chronicity in whom the likelihood of reversibility is too small to justify further 
immunosuppressive therapy42. 
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Indications for a renal biopsy in SLE patients include:42 
 
Hematuria and proteinuria; 
 
Renal dysfunction; 
 
Hypertension; 
 
Low levels of the complement factor C3; 
 
The presence of chronic renal lesions; and modifications in  
 
therapy: initiation, changes, or discontinuation. 
 
Renal biopsy can provide 3 mainstays of the final diagnosis: classification, extent  
 
of reversibility and chronicity of the renal disease, and outcome prediction. Limitations  
 
are represented by the need to obtain renal  cortical tissue and to collect adequate  
 
specimens, as well as the evaluation of focal lesions with limited sampling of highly  
 
heterogeneous glomerular involvement42. Also proliferative disease may occasionally be  
 
present with no clinical and lab parameters suggestive of renal involvement. 
 
Classification of lupus nephritis 
 
Different classification systems for lupus nephritis have been suggested but the 
WHO classification, published in 1982 and subsequently revised in 1995, has in the past 
been the most widely used. The WHO system classifies glomerular involvement 
according to the extent and pattern of immune deposits and inflammation, which are 
detected by immunohistochemistry on light microscopy. The finding of positive staining 
for immunoglobulin (Ig)G, IgM and IgA, together with staining for C1q, C3 and C4, is 
known as ‘full house’ and is present in up to 25% of patients with lupus nephritis and 
almost never in patients with non-lupus disease. The WHO system does not assess 
glomerular activity, involvement of the renal tubules, blood vessels or chronicity of 
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interstitial damage. The limitations of the WHO system have led to modifications 
recently being suggested by the International Society of Nephrology/Renal Pathology 
Society (ISN/RPS)43. The ISN/RPS classification is summarised in Table 2. 
 Activity and Chronicity indices (Table 1) are being provided to the  
 
clinician for LN patients, as they represent predictors, although weak, of long-term  
 
prognosis. Such a weakness may be related to the still-lingering interobserver and  
 
intraobserver variations. A value of 1+ corresponds to an involvement of < 25%, 2+  
 
to 25% to 50%, and 3+ to > 50%. As reported by different investigators, negative  
 
prognostic indices include crescents in more  than 30% of the glomeruli, a chronicity  
 
index > 5, male sex, and a higher lesion activity in the glomeruli36. 
 
Repeat renal biopsy 
 
Repeat biopsy at times of deteriorating renal function, new microscopic 
haematuria or proteinuria provides useful information and can be useful in helping to 
determine renal prognosis44. It can help: 
• to confirm the presence of a clinically suspected renal flare 
• in the assessment of chronic damage and progression 
• in guidance of treatment duration, and to assess whether proteinuria is due to 
ongoing disease activity or chronic damage. 
• to document class switching.  
 
The new classification is expected to simplify diagnosis, reporting, therapy, and  
 
followup, although some challenges still need to be tackled, including the high  
 
heterogeneity of LN and the limited classification of tubular lesions. The association of 
LN with antiphospholipid antibodies also has a significant effect on prognosis because it 
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leads more frequently to irreversible organ damage, with destruction of most renal 
findings, hence, the lack of association with a specific LN class. The addition of gene  
microarray results may lead to further improvements and refinements of this  
interim, working classification45. 
 
TABLE 1: NIH RENAL PATHOLOGY SYSTEM36  
ACTIVITY INDEX CHRONICITY INDEX
Glomerular abnormalities  
1. Cellular proliferation 1. Glomerular sclerosis 
2. Fibrinoid necrosis, karyorrhexis 2. Fibrous crescents 
3. Cellular crescents  
4. Hyaline thrombi, wire loops  
5. Leukocyte infiltration  
Tubulointerstitial abnormalities  
1. Mononuclear cell infiltrates 1. Interstitial fibrosis 
 2. Tubular atrophy 
Severity of each index quantitated as 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. 
Fibrinoid necrosis and cellular crescents are weighted by a factor of 2. Maximum activity 
index is 24 and that of chronicity index 12. 
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Table 2. International society of nephrology/renal pathology society classification of 
lupus nephritis (2003). 
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Management  
The management of lupus renal disease ultimately should be based on risk 
stratification and the prognostic information available clinically or by renal biopsy.  
WHO CLASS I 
Class I nephritis which is defined by normal histologic findings requires no 
specific therapy7, 12, 46. Here, therapy depends on extent of extra renal involvement. 
WHO CLASS II-MESANGIAL  
Class II-A mesangial lupus nephritis with mesangial deposition of 
immunoglobulin if unaccompanied by proteinuria and active urinary sediment does not 
require treatment. Class II-B mesangial lupus nephritis when accompanied by significant 
proteinuria (e.g.: greater than 1 gram per day) usually requires treatment with steroids, 
especially if accompanied by hematuria, leukocyturia, other evidence of active urinary 
sediment, elevated anti-double stranded DNA, or low C37. These patients may be treated 
with between .5 and 1 mg/kg of prednisone or equivalent per day for from four to twelve 
weeks. Subsequently, steroids are tapered by 5-10 mg. increments every 1-3 weeks7.  
WHO CLASS III and IV(PROLIFERATIVE)  
A recently published 2004 Cochrane systematic review analysed all published 
therapeutic trials for proliferative lupus nephritis and found that 25 of 920 articles were 
eligible for consideration, with a total of 909 patients across all therapeutic 
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combinations47. The review found that the use of cyclophosphamide with steroids 
reduced the risk of doubling serum creatinine, compared with steroids alone, but had 
no impact on overall mortality. The risk of ovarian failure was significantly increased 
with the use of cyclophosphamide. Azathioprine with steroids reduced the risk of death 
but had no effect on renal outcomes compared with steroids alone. As trials from 1971 to 
2002 were included, interpretation of the review is limited by the variable range of drug 
doses used over this time period. Routine dosages of steroids have been significantly 
reduced during this time. Trials using both oral cyclophosphamide and intravenous 
cyclophosphamide regimens were pooled, with large variations in cumulative doses of 
cyclophosphamide administered. Despite these provisos, the use of cyclophosphamide 
with steroids to preserve renal function in patients with diffuse, proliferative, lupus 
nephritis was recommended. 
Long-term treatment with cyclophosphamide for patients with proliferative lupus 
nephritis is associated with adverse effects, including an increased risk of infection (10–
18% per year). Oral cyclophosphamide is associated with an increased risk of herpes of 
19%, compared with 9% for intravenous cyclophosphamide regimens, and with an 
increased risk of ammenorrhoea in 50% compared with 29% for intravenous 
cyclophosphamide therapy14. Cumulative doses of cyclophosphamide over 9 g, 
particularly in women over the age of 32 years, are associated with ovarian failure15, 16. 
Reversible alopecia can occur in 20% of patients treated with cyclophosphamide48. 
Bladder toxicity (in 14–17%) is well reported particularly with the older treatment 
regimes but now occurs less frequently, particularly with the use of pre-treatment 
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hydration13, 48. The aim of treatment therefore, is to induce and maintain remission of 
active nephritis with minimum toxicity.  
Therapeutic regimens to treat proliferative lupus nephritis can be divided into 
those therapies aiming to induce remission of renal disease and those maintaining the 
renal remission achieved. 
Induction therapy 
 
The aim of treatment is to achieve a rapid clinical renal remission, as this is 
associated with an improved long-term renal prognosis. 
Cyclophosphamide 
 
Cyclophosphamide, as outlined above, can be used for this phase of treatment. 
Most units now use intravenous regimens because this reduces the cumulative dose 
administered. The later lupus nephritis trials at the National Institutes of Health (NIH) 
used pulsed intravenous cyclophosphamide at 0.5–1 g/m2 given monthly for 6 months, 
then every 3 months for a further 2 years38. This regimen was subsequently used by many 
for the treatment of active proliferative lupus nephritis. Recently, dosing regimens have 
been adjusted by many units with 6–12 months of therapy using 6–8 pulses of 
cyclophosphamide now commonly being used, assuming renal remission is achieved 
during this time49. 
In the Euro-Lupus trial of 90 patients, a shorter course of cyclophosphamide 
therapy of 0.5 g fortnightly for six doses was compared with the 20-month intravenous 
cyclophosphamide regime. After a median follow-up period of 73 months, no difference 
was found between the two groups for the end-points of ESRD or doubling of serum 
creatinine. All patients included in this trial had proliferative glomerulonephritis but only  
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22% of them presented with renal impairment, and 28% with nephrotic syndrome. Also 
few Black or Afro-Caribbean patients, whose prognosis is poorer, were included in the 
study49. 
Cyclophosphamide is an effective induction agent in the majority of cases but 
22% of patients might have disease refractory to cyclophosphamide50. Adverse effects of 
cyclophosphamide, particularly infertility, are of concern as most patients with lupus 
nephritis are of child-bearing age. There is, therefore a need for alternative agents for 
disease induction or for cases refractory to cyclophosphamide. 
Mycophenolate mofetil (MMF) 
 
MMF is an immunosuppressant that is successfully used in solid organ 
transplantation and has been used to good effect in the treatment of lupus nephritis and 
other immunemediated glomerular disorders51. MMF has been used for induction therapy 
in newly diagnosed active lupus nephritis and also for those patients with lupus nephritis 
refractory to cyclophosphamide therapy. Prospective trials for remission induction in 
lupus nephritis are summarised in Table 452- 59. MMF is teratogenic in animal studies and 
is therefore contraindicated during pregnancy but there is no current consensus on 
preconception advice for women on MMF wanting to become pregnant. 
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Table 4. Prospective trials in lupus nephritis using mycophenolate mofetil52-59. 
 
 
Asperva Lupus Management Study60 reported  the comparison of MMF and 
intravenous Cyclophosphamide (IVC) as induction treatment for active lupus nephritis in 
a multinational, two-phase (induction and maintenance) study. 370 patients were 
randomly assigned with classes III through V lupus nephritis to open-label MMF (target 
dosage 3 g/d) or IVC (0.5 to 1.0g/m2 in monthly pulses) in a 24-wk induction study. Both 
groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The 
primary end point was a prespecified decrease in urine protein/creatinine ratio and 
stabilization or improvement in serum creatinine. Secondary end points included 
complete renal remission, systemic disease activity and damage, and safety. Overall, they 
did not detect a significantly different response rate between the two groups: 104 (56.2%) 
of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary 
end points were also similar between treatment groups. There were nine deaths in the 
MMF group and five in the IVC group. They did not detect significant differences 
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between the MMF and IVC groups with regard to rates of adverse events, serious adverse 
events, or infections. MMF was at least equivalent to IVC in inducing remission. 
Although most patients in both treatment groups experienced clinical improvement, the 
study did not meet its primary objective of showing that MMF was superior to IVC as 
induction treatment for lupus nephritis60.  
 
Maintenance Therapy 
 
The aim of this phase in treatment is to maintain renal remission without 
compromising patient long-term morbidity. Renal flare or relapse is associated with a 
worse longer term renal outcome. Optimum duration of maintenance therapy is unclear. 
 
Azathioprine 
 
Azathioprine is the most commonly used drug for maintenance therapy in lupus 
nephritis. The recent systematic review by Flanc et al reported found that azathioprine 
with steroids did not improve renal outcome compared with steroids alone in the 
treatment of diffuse proliferative lupus nephritis47. A prospective trial comparing 
azathioprine with cyclophosphamide is underway in the Netherlands61. A European trial 
(EULAR) randomised 32 patients with diffuse proliferative lupus nephritis to either pulse 
intravenous cyclophosphamide with methylprednisolone for 24 months compared with 
daily oral Cyclophosphamide followed by azathioprine. Two patients in the azathioprine 
group reached ESRD and required dialysis; none in the pulsed cyclophosphamide group 
reached this stage. Three deaths occurred in the continuous cyclophosphamide group and 
one in the azathioprine group. No statistically significant differences between the two 
regimens were found62. 
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Mycophenolate mofetil (MMF) 
 
Azathioprine has well-documented adverse effects and 10% of patients can 
produce a hypersensitivity reaction or be intolerant. MMF has therefore been used as an 
alternative maintenance agent. Contreras et al reported a comparison of MMF, 
azathioprine and pulsed intravenous quarterly cyclophosphamide as maintenance 
therapy in proliferative lupus nephritis63. All 59 patients received monthly pulsed 
intravenous cyclophosphamide for a maximum of 7 months before being randomised to 
receive the maintenance therapies. During treatment, four patients in the 
Cyclophosphamide group and one in the MMF group died. ESRD developed in three of 
the cyclophosphamide group and in one each in the azathioprine and MMF groups. 
Interestingly, the relapse-free survival was higher in the MMF group than the 
cyclophosphamide group (P= 0.02) and the number of infections was lower in the MMF 
and azathioprine groups63. 
The European Working Party on Systemic Lupus Erythematosus has recently 
concluded a new trial, MAINTAIN, to compare MMF with azathioprine as remission 
maintaining treatment in diffuse, proliferative, lupus nephritis. A 3-month course of the 
low-dose cyclophosphamide regime was administered initially18. The study showed 
equivalent efficacy for MMF and Azathioprine. 
Cyclosporine 
 
This agent has been used to treat membranous nephropathy associated with lupus 
(class V) and found to induce remission in all of the 24 patients over a 24-month period. 
High relapse rates on withdrawal of the cyclosporine were noted64. Cyclosporine as an 
adjunctive therapy in three patients with proliferative lupus nephritis, resistant to 
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intravenous cyclophosphamide, with favourable outcome have been reported65.Concerns 
as to nephrotoxicity have limited its routine use. 
Mizoribine 
 
This drug has the same mechanism of action as MMF. It was developed in Japan 
and has been used in some patients with flares of proliferative lupus nephritis; it 
significantly reduced proteinuria and anti-dsDNA levels. Repeat biopsies in these patients 
documented histological improvement. At present its use is limited to Japan66. 
WHO CLASS V-MEMBRANOUS  
Class V membranous lupus nephritis is often treated at the outset with 1 mg/kg 
per day of prednisone or equivalent for six to twelve weeks. Regardless of a response, 
steroids are usually then discontinued. Cyclophosphamide is generally reserved for those 
patients who have a concurrent proliferative component with their lupus membranous 
nephritis and continue to have clinical features of activity which typically requires not 
only proteinuria but either an active urinary sediment, persistent high anti-DNA, or 
hypocomplementemia. Therefore, patients with lupus membranous nephropathy and 
persistent nephrotic syndrome who have a component of proliferative nephritis are 
considered for cytotoxic therapy. Patients with pure membranous nephritis and incessant 
nephrotic syndrome are candidates for therapy with cyclosporin67. The dose typically is 
3.5 mg to 5 mg/kg per day with close monitoring of the blood pressure and for a 
paradoxical effect on the serum creatinine reflective of the nephrotoxic effects of this 
agent. An additional mechanism of injury in patients with lupus nephritis relates to the 
hypercoagulability that accompanies the anti-phospholipid antibody syndrome. These 
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patients may develop hypertension, proteinuria, urinary sediment and abnormal renal 
function. These patients are candidates for therapy with anticoagulation or anti-platelet 
agents.  
WHO CLASS VI-GLOMERULOSCLEROSIS 
Improvement in this class, has been attributed to a number of different factors 
including the more judicious use of corticosteroids, refinements in immunosuppressive 
therapy, more effective treatment of hypertension and cardiovascular disease, and greater 
availability of dialysis and renal transplantation68. 
In the routine management of lupus renal disease, the addition of plasmapheresis 
to steroids and cyclophosphamide compared to steroids and cyclophosphamide alone, 
proved of no benefit69. Plasmapheresis is most useful in lupus patients with thrombotic 
microangiopathic hemolytic anemia or secondary thrombocytopenic purpura (TTP). The 
renal disease that accompanies this syndrome is clearly responsive to plasmapheresis 
with plasma exchange. Synchronized plasmapheresis based on the theory of "stimulation 
depletion" was initially reported to be of benefit47. Synergism between pheresis and 
cytotoxic treatment was predicated on the concept that plasmapheresis is followed by a 
period of accelerated B cell proliferation such that synchronized doses of 
cyclophosphamide would have the greatest cytolytic effect on autoreactive anti-DNA 
producing clones of lymphocytes. However, a more recent study suggested that 
synchronization was of no greater benefit than standard cyclophosphamide and low dose 
prednisone treatment yet associated with greater toxicity70, 71. 
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Intravenous immunoglobulin is a relatively less toxic, although expensive 
approach to the treatment of lupus and lupus renal disease. However, save for scattered 
case reports, there is no convincing data to state with any certainty its benefits. 
Intravenous immunoglobulins can be associated, albeit rarely, with acute renal failure; 
presumably on the basis of tubular injury related to the infused immunoglobulin and the 
vehicle used. 
Novel Immunotherapies 
Rituximab 
Rituximab is an mouse/human anti-CD20L antibody and is used in the treatment of 
lymphoma. CD20 is a 33–37 kDa, non-glycosylated phosphoprotein expressed on the 
surface of almost all normal and malignant B cells but not on plasma cells. B-cell 
depletion is producing promising results in preliminary studies of SLE, including 
refractory diffuse, proliferative, lupus nephritis. Typical regimens have employed four 
infusions of rituximab (375 mg/m2) weekly for four weeks with intravenous pulsed 
cyclophosphamide72. Regimen used in this study by Fra GP et al was consolidation phase 
with 1.Cyclophosphamide 20mg/kg i.v. every 28 days for 3 cycles, 2.Rituximab 
375mg/m2 i.v. weekly for four weeks, and 3.slow maintenance treatment with 
methotexate, cyclosporine and low dose prednisolone72. Phase I/II trials of rituximab in 
SLE have shown it to be well tolerated and safe, with B-cell depletion being profound in 
the majority of patients. This was associated with an improvement in disease activity 
scores73.  
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 The moderate sized phase II/III trials EXPLORER and LUNAR that tested 
Rituximab, an anti-CD 20 monocloal antibody, for treatment of non-renal and renal 
lupus, disappointed many investigators with anecdotal success in refractory patients. 
These rituximab trials were intended to detect a large clinical effect in patients with very 
active disease and this was not found. However, additional studies in targeted populations 
or with a change in design to detect smaller or longer term effect is warranted74, 75. 
Anti-BLys therapy 
B-lymphocyte stimulator (BLyS) is a protein discovered by Human Genome 
Sciences. It is required for the development of B-lymphocyte cells into mature plasma B 
cells. LymphoStat, a human monoclonal aAnti-BLyS antibody, specifically recognizes 
and inhibits the biological activity of BLyS. Dysregulation of BLyS over extended 
periods of time is common in patients with SLE76. Phase I trials in SLE have documented 
a reduction in B cells and anti-dsDNA levels without toxicity. The most promising 
studies were BLISS 52 and BLISS 76, large phase III studies that demonstrated 
measurable efficacy for Belimumab, a monoclonal antibody against B cell activating 
factor (BAFF)75. 
Table 5. Novel immunosuppressive/modulatory therapies for SLE77 
B cell targeted therapies 
  B cell depletion 
Anti CD 20 mAb 
  Anti CD 22 mAb- Epratuzumab 
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 B cell survival factors 
  Anti BLyS mAb 
  TACI Ig 
  Anti BLyS and APRIL mAb- Atacicept 
Tolerogen 
 LJP 394 
Co stimulatory blockade 
 CTLA4-Ig 
 Anit CD 40 ligand mAb 
Anti cytokine therapies 
 Anti IL10 mAb 
Anti TNF α 
Anti complement therapy 
 Anti C5b-9 mAb 
Non specific immunotherapy 
 Intravenous immunoglobulin 
 Bone marrow transplantation 
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Fig 3. Mechanisms of current immunotherapies.  
 
 
 
Therapeutic drug monitoring for mycophenolic acid in SLE 
 
Mycophenolate mofetil (MMF) has become the most frequently used 
immunosuppressive drug in kidney transplant recipients. Since its approval for the 
prevention of acute rejection after kidney transplantation in 1995 in the USA and in 1996 
in Europe, the use of azathioprine has been rapidly diminishing, giving way to the use of 
MMF. A second formulation of mycophenolic acid (MPA), the active metabolite of 
MMF, has become available as enteric-coated mycophenolate sodium (EC-MPS). 
Randomized clinical trials have shown that EC-MPS 720 mg b.i.d. is therapeutically 
equivalent to MMF 1000 mg b.i.d. with a comparable safety profile. These equimolar 
doses of EC-MPS and MMF produce equivalent MPA exposure. The delayed release 
formulation, EC-MPS, exhibits more variable pre-dose MPA concentrations and more 
variable peak concentrations78. 
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Optimal Dosing 
 
Initially, in patients with lupus nephritis MMF doses of up to 2 g daily were used. 
Subsequent dosing regimens started with 1 g MMF/day and titrated on a weekly basis up 
to a maximum of 3 g/day19. A similar dose escalation is used in the ALMS trial. It is 
questionable whether standard dose therapy is the best way to treat a patient, given the 
large inter-individual variability in pharmacokinetics20. In renal transplant patients, 
monitoring of MPA exposure to optimize MMF treatment is a heavily debated topic 79- 
82.Several studies have shown a correlation between MPA exposure and efficacy 83. This 
is remarkable, as most renal transplant patients are being treated with three or sometimes 
four immunosuppressive drugs in the first months after transplantation. Apparently 
exposure to only one (MPA) of these three or four drugs is so important that it affects the 
incidence of acute rejection in these patients. Recently, a French study showed a reduced 
incidence of acute rejection in concentration-controlled MMF-treated renal transplant 
recipients compared to treatment with a fixed dose regimen 84. Since patients with 
autoimmune diseases are regularly treated with only one or two immunosuppressive 
drugs, an adequate MPA exposure may be more important compared to renal transplant 
recipients receiving multiple immunosuppressive drugs. Also, in patients treated for 
autoimmune diseases MPA has highly variable pharmacokinetics, and dose is a poor 
predictor for MPA exposure 21. Factors affecting the inter individual variability of MPA 
have been extensively investigated in transplant patients and are likely the same for lupus 
patients, as they are drug related 85, 86. Patients with a poor renal function (creatinine 
clearance<25 mL/min) and patients with low albumin (<32 g/L) are known to have lower 
MPA exposure. This is explained by the fact that the clearance of MPA depends on its 
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non-protein bound fraction 87. Hypoalbuminaemia, as well as renal insufficiency, results 
in a higher free fraction of MPA, and this higher free fraction results in a higher MPA 
clearance. Other factors influencing MPA pharmacokinetics are listed in Table 6. If in 
patients with autoimmune diseases MPA exposure can be shown to correlate with either 
efficacy or toxicity, then therapeutic drug monitoring could contribute to optimize patient 
care. 
 
Correlating MPA exposure to clinical outcome 
 
Neumann et al. reported on the value of measuring MPA plasma concentrations in 
patients with autoimmune diseases 88. The study consisted of two parts. In the first part of 
the study the correlation between 12-h trough MPA concentrations and full area under the 
concentration–time curve (AUC) of MPA was investigated. Despite a rather weak 
correlation between trough and AUC the authors decided to longitudinally monitor a 
cohort of patients in the second part of the study, collecting serial trough values, which 
were linked to the occurrence of adverse events and to disease recurrence. Optimal 
efficacy, i.e. prevention of recurrence to active disease, was associated with higher MPA 
trough concentrations (> 3.0 mg/L). A remarkable finding is the observation that in this 
study adverse events were clustered in patients with a high MPA exposure. This is in 
contrast with studies in renal transplant patients, in whom tolerability was poorly 
correlated with MPA concentrations. The authors defined the upper threshold of the 
therapeutic window based on toxicity. In renal transplant patients, the upper threshold of 
the therapeutic window is not based on increased toxicity, but merely on a lack of further 
improvement of efficacy above a certain exposure. 
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Table 6. Factors affecting MPA pharmacokinetics87 
 
 
 
 
When C12h values were subject to regression analysis, a significant association 
with AUC0–12h was observed (r = 0.545, P < 0.001). The corresponding regression line 
is shown in Figure 4. If those patients were counted who achieved an MPA exposure 
within 40–75 hmg/L (i.e.close to the range of 30–60 mgh/L recommended for transplant 
recipients), then 24/38 patients (63.2%) met this AUC range, whereas 5 (13.1%) and 9 
(23.7%) were below and above this target, respectively. Hence, an MPA12-h trough 
level of  ∼3mg/L was considered an appropriate surrogate for providing autoimmune 
disease patients with an adequate MPA exposure and was chosen for monitoring 
immunosuppression in subsequent 12-h trough levelstudies. 
 The association of MPA trough levels with reoccurrence of disease and MPA 
toxicity is displayed in Table 7. Of the 13 SLE patients, 8(62%) experienced one or more 
flares; all were of minor severity (new B score according to the BILAG index) 
comprising arthralgia/arthritis and/or myalgia and cutaneous manifestations (some with 
ulcers). Generally, lower MPA trough levels were associated with disease recurrence. 
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Remission persisted in all patients with 12-h MPA trough levels  ≥3.5mg/L. An MPA 
level of 4.5 mg/mL best discriminated between patients with and without adverse events. 
Fig 4. Relationship between mycophenolic acid (MPA) plasma concentration at 12 h 
(C12 h) andAUC0–12 h for MMF following an oral dose of 1 g in patients with 
autoimmune disease88. 
 
 
 
There was no relationship apparent between MMF dose and clinical end points. 
Likewise, the amount of MMF necessary to achieve MPA levels close to the targeted 
trough (around3mg/L), showed a wide range as depicted in Table 888. 
 
Unanswered questions 
 
Neumann et al. are careful in the interpretation of their data. They acknowledge 
that this is an exploratory study. The therapeutic window of MPA concentrations between 
3.5 and 4.5 mg/L may serve as a starting point for prospective studies, but is subject to 
change. Prospective studies should be adequately powered to deal with other patient or 
disease characteristics influencing the propensity to relapse. Although homogeneous 
patient populations would be preferred for establishing correlations between drug  
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Table 7. Relationship between mycophenolic acid (MPA) 12-h trough levels and 
clinical outcome in patients with SLE (N = 13)88 
 
 
 
 
 
 
 
 
 
Table 9. Relationship between mycophenolic acid (MPA) 12-h trough levels and 
MMF dose administered in patients with autoimmune disease (N = 39)88 
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exposure and clinical outcome, in reality patients with lupus nephritis form rather 
heterogeneous populations, and we want to get a better idea of optimal target levels in 
patients with a lower or higher risk of relapse. In the study by Neumann et al., patients 
were not suffering from the more severe stages of autoimmune diseases. Obviously, this 
may have consequences for optimal target concentrations. For routine clinical practice, 
trough concentrations are more practical compared to obtaining a full AUC. Given the 
poor correlation between trough and AUC, for prospective trials it would be better to use 
a more robust measurement of MPA exposure than troughs only89. As an alternative to 
the latter abbreviated sampling strategies may be used to accurately estimate AUC90. 
 
What can we do now? 
 
The data presented should not be considered strong evidence in favour of MPA 
monitoring. Nor should their predictions of a therapeutic window be looked upon as an 
established guidance for routine clinical practice. We need more 
pharmacokinetic/pharmacodynamic analyses to decide on the value of therapeutic drug 
monitoring for MPA in this patient population. For current patient care, however, even at 
this moment measurement of MPA plasma concentrations can be of some help. In 
patients with lupus nephritis in whom MMF is used as induction therapy, one would 
expect to see a clinical response within a period of 1 month in most patients. If, after 1 
month of therapy, in non-responders MPA (trough) plasma concentrations are found to be 
low (say <2 mg/L), then a dose increase may have favourable effects on the likelihood of 
reaching remission. However, if in the same patient MPA trough is >4.0 mg/L already, 
then a further dose increase does not seem to be a good idea, as it may cause toxicity 
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without additional benefit in efficacy. In such patients switching to another agent may be 
the preferred way to go89. 
Outcomes for Clinical Trials in Lupus Nephritis 
 
The most important requirement for lupus nephritis trials remains an adequate 
period of follow-up—ideally for 5–10 years. Design and reporting of trials in lupus has 
been criticised90, 91. For lupus nephritis trials, the following outcomes are commonly 
used: 
• doubling of serum creatinine 
• time to renal remission 
• time to renal flare. 
The definition of renal remission and flare varies between investigators but usually 
implies stable renal function, inactive urinary sediment with no haematuria or pyuria 
and proteinuria of less than 0.5 G/24 hours. Use of proteinuria as a separate endpoint is 
not recommended because of the difficulties in differentiating persistent proteinuria 
due to chronic damage from that due to persistent disease activity. Further outcome 
measures would include complication rates due to treatment, such as infections requiring 
hospitalisation and change in overall lupus disease activity. 
Predictors of Outcome 
 
Owing to the high heterogeneity of SLE among patients and the limited  
 
therapeutic resources available at present that may induce substantial toxic effects in the  
 
long term92, it is important to identify those patients who may have a worse prognosis,  
 
and thus necessitate more-aggressive treatments to prevent or reduce complications and  
 
organ failures. 
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The predictors of outcome and long-term prognosis in patients with lupus  
 
nephritis are93,94,   
 
1. Disease severity, both in terms of clinical manifestations (serum                         
 
creatinine and proteinuria) and histopathology; 
 
2. Patients' characteristics: age and sex, race and ethnicity,  
 
socioeconomic status and access to healthcare; 
 
3. Response to therapy; and 
 
4. Specific treatment modalities. 
 
Old data published by Estes and Christian95 in the 1970s pointed to an estimated  
 
5-year survival rate for patients with renal manifestations of about 50% vs. 75% for the  
 
whole SLE series analyzed. Such a rate was even lower for patients with severe kidney  
 
disease: about 68% for patients with focal proliferation, but only 28% for those with  
 
diffuse and membranous lesions. Patients in this series were being treated with 40 mg of  
 
prednisone, the conventional treatment at the time, as other immunosuppressive agents 
were not yet in use 95. 
In a 1965-1998 series of 800 patients followed at SUNY/Brooklyn, the average  
 
survival rate of SLE patients with kidney disease was, overall, 60% to 65% at 300-350  
 
months96. 
 
Of note, the effect of the inclusion of socioeconomically disadvantaged patients  
 
had a far less negative effect than reported in other series. It showed a trend, but it did not  
 
reach a significant difference. It is unclear whether the socioeconomic factors did not  
 
play such a significant role in this cohort or whether better care than average was  
 
provided to these patients. 
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Notwithstanding these successes, and the fact that SLE-related mortality has been  
 
significantly reduced with medical intervention in the past 20 years or so, there has been  
 
a 3-fold increase in morbidity, thus leading to an increase in the overall burden of  
 
disease. 
 
A number of other factors have been shown to be of critical importance in  
 
predicting worse outcomes for patients with severe LN in a study of 65 patients97: 
 
1. Initially high serum creatinine; 
 
2. Lower hemoglobin/hematocrit; 
 
3. Black race; and 
 
 
4. The presence of interstitial fibrosis and crescents (which are a sign of  
 
chronicity and damage). 
 
 
Role of Antiphospholipid syndrome (APS) in Lupus Nephritis 
 
 APS is characterized by recurrent arterial or venous thrombotic events and/or 
pregnancy morbidity along with the sustained presence of antiphospholipid antibodies 
(anticardiolipin antibodies and/or lupus anticoagulant)98. Renal disease in 
antiphospholipid syndrome is characterized by interstitial tubular or glomerural injury 
due to obstruction of large, medium, or small-sized vessels99. In a recent study, 
Vlachoyiannopoulos et al studied renal involvement in a cohort of 248 patients with SLE 
and APS syndrome with positive titer of anticardiolipin antibodies, among which 40 % 
had evidence of renal involvement100. A renal biopsy was performed in 79 % of patients 
for diagnostic purposes. Patients with APS experienced high percentages of hypertension 
(59 %) compared to those without the syndrome, while increased levels of creatinine, 
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proteinuria, and hematuria with or without the presence of casts were similar in both 
groups. Renal biopsy analysis revealed that the main histopathologic finding in APS 
patients compared to controls was hyperplasia of intima (64 % vs. 19 %, p<0.001). 
Thrombi and atrophy of renal tubules were common but not pathognomic, since they 
were found in both groups. Renal biopsy findings determined further therapeutic 
approach to these patients. When findings are consistent with lupus nephritis, according 
to World Health Organization (WHO) classification, standard care with intravenous 
cyclophosphamide pulses and corticosteroids is recommended101. When thrombi and 
intimal hyperplasia predominate, the patient should be placed on long-term oral 
anticoagulant therapy.  
 
LN: Therapy and Prognosis 
 
 The natural outcome of lupus nephritis is difficult to predict because many 
patients will have already received corticosteroids or other immunosuppressants. Long-
term follow-up studies have demonstrated that, with treatment, patient survival is 72% at 
10 years and 61% at 20 years. This compares with 5-year survival rates of 17% in the 
1950s of patients with class IV disease102. Preservation of renal function is less 
encouraging, with reports of 5-year renal survival with treatment of 46–95%93. 
Retrospective studies have suggested prognostic factors at disease presentation to identify 
those patients at risk of development of ESRD. These factors can be divided into renal or 
non-renal. 
In the decade from 1990 to 2000 there was significantly less proteinuria (46 v 17  
 
g/l, p=0.008), significantly lower rates of renal failure (40% v 17%, p=0.02), and fewer  
 
histological signs of chronicity (33% v 10%, p=0.01) at the time of diagnosis of LN than  
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in the decade from 1980 to 1989103. The mean ± (SD) time from the first appearance of  
 
proteinuria until kidney biopsy was significantly shorter in the later decade [15.4 ± 15.6  
 
vs. 3.9 ± 4.7 months]. Although treatment schedules were not significantly different,  
 
the outcome of the disease was  significantly better in the patients who were diagnosed  
 
with LN between 1990 and 2000 (p=0.045)103. 
 
A number of factors have prognostic significance from a clinical point of view, as  
 
outlined by Dr. James Tumlin104of Emory University, Atlanta, Georgia, including  
 
persistent anemia, severity of the disease,105, 106 time to treatment, and duration of  
 
remission. In patients treated with intravenous cyclophosphamide, an age at diagnosis of  
 
< 29 years was found associated with a higher risk of progression to LN in 5 years. Also,  
 
an advanced chronicity index (> 3) at biopsy and a delay to treatment of > 5 months  
 
were linked to worse outcomes107.  
 
Patients who did not have a flare-up of their disease had only a 25% risk of  
 
doubling their serum creatinine in 5 years vs. a 75% risk in patients who experienced  
 
flare-ups in the observation period. Austin and colleagues97 reported in 1994 that the  
 
presence of focal necrosis, crescents, proteinuria, lower C3 (< 76 mg/dL) following  
 
therapy, female sex, age > 30 years, black race, and hematocrit of < 26% were associated  
 
with a worse outlook. The difference reported by the 2 groups in age significance has not  
 
been clarified. Treatment can critically improve the survival of SLE patients with renal  
 
disease. In a study by Laitman and colleagues38, patients in group 1a (with  
 
relapsing/recurrent grades 2, 3, and 4 LN) had a survival of about 80% at 6 years vs. less  
 
than 5% for patients in group 1b who also had grades 2, 3, and 4 LN, but were refractory  
 
to medical treatment. Patients in group 2 (with grades 3 and 4 LN) with recurrent disease  
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had an intermediate survival rate. 
 
If patients were treated within 5 months of diagnosis, they had a 25% chance of  
 
relapse of their renal disease at 7-10 years. Conversely, if they were treated only after 5  
 
months from biopsy, their chances of relapse increased to 60%107. 
 
Use of renal biopsies is critical in the management of lupus patients in diagnostic,  
 
therapeutic, and prognostic terms97. The presence of cellular crescents and interstitial  
 
fibrosis was found associated, in addition to endocapillary proliferation, with an  
 
increased risk of progression (doubling of serum creatinine) in 40-50 months from 20%  
 
to 80% of cases. A global disease activity of < 1.73 was associated with progression  
 
(doubling of serum creatinine) at 4000 days in only 15% of cases vs. 80% in patients with  
 
a disease activity of > 1.73108. Persistent inflammation and positive findings at  
 
immunofluorescence are also predictive. Progression was seen in 75% of patients with  
 
karyorhexis vs. 26% in patients who were negative. Similarly, progression was seen in  
 
69% of patients with crescents vs. 33% of control patients. Reinduction therapy with  
 
pulse steroids and intravenous cyclophosphamide in 12 refractory LN patients, however,  
 
achieved a reduction of progression risk from 34% to 10.5% in patients with crescents,  
 
and from 73% to 6.4% in patients with biopsies positive for endocapillary proliferation.  
 
Follow-up biopsies at 6 months were negative for cellular crescents, endocapillary  
 
proliferation, and karyorhexis. Thus, Dr. Tumlin104 concluded that reinduction therapy  
 
was effective in salvaging LN patients who were otherwise refractory to treatment. 
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METHODOLOGY 
 
 
Study Design  Cohort Study 
 
 
Duration Of Study  August 2007 to December 2009 
 
 
Inclusion Criteria   
 
1. Diagnosis of ISN/RPN 2003 Class III/IV LN, with either active or 
active/chronic disease 
2. 13-75 years of age 
3.  MPA as induction and/ or maintenance therapy 
4. At least one follow up visit 
5. MPA AUC available  
 
 
Exclusion Criteria  
 
       
1. Age </=12 years 
  
Study Protocol 
 
  All consecutive patients diagnosed to have biopsy proven lupus nephritis 
were enrolled into the study. All patients were started empirically at 30mg/kg of 
Mycophenolate Mofetil (MMF). The equivalent dose for Mycophenolate sodium (MNS) 
is 720mg for every 1000mg of MMF78. After a minimum of 5 days of empiric therapy, all 
patients underwent therapeutic drug monitoring using abbreviated 6 hour MPA 
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(Mycophenolic Acid) Area Under the Curve (AUC). The therapeutic range considered 
adequate was 30-60 mg.h/L which has been extrapolated from the data in post renal 
transplant patients83. These patients also received oral steroids 1mg/kg/day for 2-4 weeks 
followed by 1mg/kg/alternate days tapered to 5-10mg per alternate days over next 4-6 
weeks. They may or may not have received ACEIs/ARBs. Demographic, clinical and 
laboratory data was collected at entry and every follow up visit. Occurrence of flares, side 
effects, toxicities, infections, need for dialysis etc. was noted foe each patient. 
 
The following specific data was collected at the time of enrolment into study  
 
through a Proforma (Annexure B): 
 
1. Demography- Age, Sex, Region, Race 
 
2. Clinical presentation of SLE 
 
3. Clinical presentation of Lupus Nephritis 
 
4. Biopsy findings of lupus nephritis 
 
5. Laboratory parameters at enrolment 
 
6. Co-morbidities 
 
7. Treatment Details 
 
8. MPA AUC  
 
The following specific data was collected at each follow up visit through a  
 
Proforma (Annexure B). 
 
 
1. Clinical and Laboratory parameters  
 
2. Outcome Variables- Complete remission, Partial remission, No Remission,  
 
Relapse. 
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3. Flares, Side effects, Toxicities, Infections 
 
4. Treatment details 
 
1. Primary outcome/s: 
1. Primary outcomes 
Definition of outcome variables- 
A. Complete remission- Inactive urinalysis (no cellular casts or hematuria with 
dysmorphic RBCs <10RBCs/hpf), reduction of proteinuria to less than <1g/24h, serum 
creatinine not more than 30% of the lowest during treatment105, 109. 
B. Partial remission- Stable serum creatinine not more than 50% of the lowest during 
treatment105, 109. 
C. Relapse- Renal flares can be classified as nephritic or nephrotic. In nephrotic (or 
proteinuric) flares, there is only increase in proteinuria (>2 g/day). Nephritic flares are 
further classified as mild, moderate or severe. A mild/moderate nephritic flare is 
characterized by active urine sediment (presence of cellular casts or hematuria with 
dysmorphic RBCs (10RBCs/hpf)), increase in proteinuria (<2 g/day for mild, >2g/day for 
moderate) but stable serum creatinine level. In severe nephritic flares there is active urine 
sediment and increase of plasma creatinine level >30% from baseline values, regardless 
of proteinuria110. 
D. ESRD- GFR <15ml/min/m2 requiring dialysis or transplantation 
2. Secondary Outcome/s: 
1. Time to complete renal remission and partial remission 
2. Change in anti dsDNA levels 
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4. Change in C3 and C4 levels 
5. Change in Proteinuria, GFR, RBCs in urine 
6. Side effects and complications of MPA 
7. Proportion of patients achieving target MPA levels 
8. Correlation of the side effects and complications of MPA with the drug levels 
attained 
 
Statistical Analysis 
 
The number of Lupus Nephritis patients who are newly diagnosed through biopsy 
each year in our department is approximately 40, and the proportion of patients with 
Class III and Class IV lupus nephritis is about 70% i.e., 28-30 patients per year. Out of 
the 30 patients, approximately one third i.e., about 10 patients per year choose to be on 
MPA considering the cost issues and side effect profile and agree to have therapeutic 
drug monitoring. Hence within a seven year study period we aimed to recruit 70 patients. 
With a 20% loss in at least one follow up, the final tally will be about 50-55 patients. 
Patients zero time corresponded to the time of Renal biopsy. It was a time based study. 
Our sample size is 52 patients. It compares well with the studies done on outcome in 
lupus nephritis. Study done in our centre by Abraham et al and published in ’99 was done 
on 29 patients with class IV lupus with a follow up of 5 years104. Other  single centre 
studies from the West38,105, 111,112,113 had sample size ranging from 34-82. 
Continuous data was presented as mean +/- SD unless otherwise specified. 
Comparison of continuous variables was by the t test or Mann whitney U test where 
approoriate. Pearson χ2 test or Fisher exact test was used for comparison of categorical 
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variables. Relapse free survival will be analysed by actuarial survival and compard by log 
rank test. 
  
Paired t Test (normal) and Wilcoxon Signed Rank Test (non normal) were  
 
performed to assess the significant improvement over time. Pearson Chi Square test were  
 
used for categorical variables. SPSS version 13 was used for the statistical  
 
analysis. 
 
 
CONSORT DIAGRAM 
 
 
68 CONSECUTIVE PATIENTS ENROLLED 
 
All patients had mean follow up of 17.1±13.3 months. 
 
 
CR- Complete remission, PR- Partial remission,  
NR- No remission, R- Relapse, D- Death 
 
 
  
52 patients with actuarial follow 
up at 3 months 
 
16 patients were lost to follow up 
CR
=16
PR
=33 
NR 
=3 
R 
=0
D 
=0
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RESULTS 
 
52 consecutive patients satisfied the inclusion criteria and were recruited 
prospectively into the study. 
 
1. The following are the demographic characteristics of the study population. 
 
 
Table A: Demographic Characteristics At Baseline 
 
 
Age (yrs)       26.6 ±11.4 (11-65) 
M:F(N)  3:49 
Weight (kg)   51.8 ±9.6 (34-73) 
SBP (mmHg) 129.6 ±15.5 (100-170) 
DBP (mmHg) 82.6 ±7.7 (70-99) 
Class III (n=52) 7 (13.5%) 
Class IV (n=52) 45 (86.5%) 
 
Figure A 
 
Hypertension at onset
4 7 %
5 3 %
B P < 1 2 0 /8 0
B P > 1 2 0 /8 0
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 2. The following are the lab parameters of the study population. 
 
 
 
Table B: Lab Parameters At Baseline 
 
 
Proteinuria (mg/d) 3184.3 ±2720.3 (81-10100) 
Urine RBCs /hpf 18.8±18 (2-60) 
↓Comp (n=35) 31 (91.2%) 
↑ dsDNA (n=49) 31 (63.3%) 
S. Creat (mg/dl) 1.0 ±0.4 (0.9 - 4.3) 
GFR (ml/min/1.73m2) 87.7 ±33.0 (29 - 174.9) 
S. Albumin (mg/dl) 2.5±0.8 (0.9 - 4.3) 
 
 
 
 
 3. All patients were started empirically at 30mg/kg of Mycophenolate Mofetil 
(MMF). The equivalent dose for Mycophenolate sodium (MNS) is 720mg for every 
1000mg of MMF78. After a minimum of 5 days of empiric dosing, all patients underwent 
therapeutic drug monitoring using abbreviated 6 hour MPA (Mycophenolic Acid) Area 
Under the Curve (AUC)90. The therapeutic range considered adequate was 30-60 mg.h/L 
which has been extrapolated from the data in post renal transplant patients117. After an 
empiric dosing schedule of 30mg per kg, 56% of patients had their MPA AUC below the 
therapeutic range of 30-60 mg.h/L and required modification of their drug dosages 
(Figure B). Very few patients had levels in the toxic range. 
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Figure B 
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  4. We plotted the MPA dose (mg/kg) before and after modification based 
on MPA AUC (Figure C). The scatter diagram to the left shows that with the empiric 
dosing schedule there was a wide variation of doses ranging from 1000 to 2000 mg per 
day. The scatter diagram to the right shows there is a significant escalation of the dose 
after the MPA AUC. Majority of them required 35mg per kg per day to reach the 
therapeutic MPA AUC of 30-60mg.h/L. 
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Figure C 
 
Exposure Controlled MPA dose
Weight 
(kg)
MPA dose at entry
(mg/day)
MPA dose modified after AUC
(mg/day)
P= 0.0
1394 ± (SE 50.6) mg/day
= 27.5 ± 1.0 mg/kg/day
1634 ± (SE 67.1) mg/day
= 32.2 ± 1.4 mg/kg/day
 
 
 
 5. The mean change in GFR (glomerular filtration rate), proteinuria and 
S.Albumin over 2 years are plotted separately to show the magnitude of change (Figures 
D,E,F). There is a significant improvement in GFR within the 1st three months and the 
improvement is sustained at 24 months. Proteinuria declined steeply over the 1st 3 months 
and the steady declined continued during the maintenance phase. Albumin similarly 
improved significantly over the 1st three months with minimal improvement there after. 
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Figure D 
Change in GFR with time
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Figure E 
 
Change in Proteinuria with time
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Figure F 
 
 
 
Change in Albumin with time
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  6. About one third went into complete remission by 3 months and it 
progressively improved to 57% by 12 months (Figure G). The complete remission rates 
improved through the maintenance phase to 88% at the end of two years. 
Partial remission was seen in 50% of the patients at three months. Cumulative remission 
which is the sum of complete and partial remission was seen in 94% at 3 months. 
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Figure G 
 
 
MAINTENANCE PHASE
INDUCTION PHASE
(n=17)
63.5
Remission status
94.3
30.8
93.5
42.5
51.0
90
56.7
33.3
100
88.2
11.8
20 40 60 80 100
24 mo
3 mo
6 mo
12 mo
%
(n=52)
(n=47)
(n=30)
Complete remission (CR)
Partial remission (PR)
Cumulative remission 
MAINTENANCE PHASE
 
 
 
 
  7. The median time to complete remission in this study was 11.1±1.3  
months (Figure H). The earliest markers of remission were an improvement in GFR and 
proteinuria to subneprotic range in 2-3 months. Anti dsDNA took a median time of 4 
months for normalization. Among Complements C4 was more specific than C3 taking a 
median time of 6 months for remission. Hence by 3-4 months we will know 
approximately which patients are likely to respond to MPA therapy. 
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Figure H 
 
  
Median time to remission
71 32 4 5 6 98 10 11 12
11.1 ± 1.3(SE) Complete remission
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4 ± 0.3(SE) dsDNA
3 ± 1.3(SE) Proteinuria <2.0G/day
2.6 ± 0.85(SE) GFR>60ml/min/1.73m2
Time (months)
 
 
 
 
 
  8. Contrary to the common belief that side effects are more likely with 
toxic levels (Figure I); neither leukopenia nor diarrhea had any correlation with the MPA 
AUC levels in this study.  
Infections were present in 7 patients and again no strong correlation with MPA AUC 
could be demonstrated. 
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Figure I 
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10. Flares were present in 7 patients (Figure J). But majority of them had mld 
nephritic flares and all resolved without any modification of immunosuppression. There 
was one death at 2 years to epsis well after stopping MMF therapy. Infections were 
present in 17% of patients in this study. 
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Figure J 
 
Complications
 Flares – 6 (11.5%)
Mild nephritic – 4
Severe nephritic – 1
Nephrotic – 1
 ESRD - 1(3.8%)
 Death – 1(0.02 %)
 Infections 
Episodes 9 (17.3%) 
Patients 7 (13.5%)
 T.B – 1 (1.9%)
 UTI – 3 (5.7%)
 LRTI – 1 (1.9%)
 Skin and mucosa – 4 
(7.7%)
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Discussion 
 
 
 52 consecutive patients satisfied the inclusion criteria and were recruited 
prospectively into the study. It compares well with the studies done on outcome in lupus 
nephritis. Study done in our centre by Abraham et al and published in ’99 was done on 29 
patients with class IV lupus with a follow up of 5 years 104. Other single centre studies 
from the West 45, 114, 115 had sample size ranging from 34-82. Follow up was through 
outpatient visits to Nephrology Out patient Clinics. 
 The mean age in this study was 26.6 ±11.4 years with a range of 11-65 years.  
The various studies from India have reported the mean age as 24 years (range 4-55 
years)2, and 25.05 years (range 7-48 years)3. This is the reproductive age group in the  
vast majority of our population. The mean age in our study was in keeping with that 
found in literature. 
The female to male ratio in this study is approximately 16:1 which is the higher 
than that reported in literature. Since this is not a prevalence study and has included only 
proliferative lupus nephritis treated with exposure controlled Mychophenolate, females 
may have been over represented. Malaviya et al in 1997 reported F: M ratio of 11:1 by 
among 1366 SLE patients from different regions of the country6. In the West the female: 
male ratio rises from 2:1 in prepubertal children up to 4.5:1 in adolescence to the 8 to 
12:1 reported  in series of adult onset patients, falling back to 2:1 in patients over 60 yr of 
age12. 
 Mean systolic blood pressure is 129.6 ±15.5 mmHg and ranged from 100-
170mmHg. Mean diastolic blood pressure is 82.6 ±7.7 mmHg and ranged from 70-
99mmHg. 53% of the study population had blood pressures >120/80 mmHg. 
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Hypertension is found to be significant in multivariate analysis as a predictor of poor 
outcome and has been validated in several studies in India and the West. A study done by 
Fiehn et al in Germany published in 2003 among 56 patients showed that histological 
signs of chronicity and either arterial hypertension or renal insufficiency, or both, was 
predictive for terminal renal failure116.  
 In this study, mean S albumin is 2.5±0.8 g/dl and range is 0.9 - 4.3g/dl. 
Hypoalbuminaemia reflects significant protein loss in urine and the underlying 
malnourished state and hence decreases the chance for a better outcome. This has been 
validated in several studies70, 71, 93, 104. Abraham et al in 1999 in a study of 29 patients 
from the same centre over a period of 5 years had shown that hypertension, nephrotic 
range proteinuria, and high activity Index were predictive of progression to end stage 
renal failure in patients with diffuse proliferative lupus nephritis104. 
 The mean GFR calculated using the abbreviated MDRD formula is 87.7 ±33.0 
ml/min/1.73m2. 
 After an empiric dosing schedule of 30mg per kg, 56% of patients had their MPA 
AUC below the therapeutic range of 30-60 mg.h/L and required modification of their 
drug dosages. Very few patients had levels in the toxic range. Neumann et al. reported on 
the value of measuring MPA plasma concentrations in patients with autoimmune diseases 
88. Optimal efficacy, i.e. prevention of recurrence to active disease, was associated with 
higher MPA trough concentrations (> 3.0 mg/L). The authors defined the upper threshold 
of the therapeutic window based on toxicity. The therapeutic range 30-60mg.h/L of MPA 
AUC used in our study has been extrapolated from the renal transplant data117. In renal 
transplant patients, the upper threshold of the therapeutic window is not based on 
 63
increased toxicity, but merely on a lack of further improvement of efficacy above a 
certain exposure. Given the poor correlation between trough and AUC, for prospective 
trials it would be better to use a more robust measurement of MPA exposure than troughs 
only89. As an alternative to the latter, abbreviated sampling strategies may be used to 
accurately estimate AUC. 6 hour MPA AUC was used in this study. 
 About 64% of this study population required dose modification after the MPA 
AUC testing. Majority of them (55.8%) were under dosed and required upward titration 
of the daily divided dose. Few (5.8%) required their doses o be reduced from the toxic 
levels. It is realized that majority would require approximately 35mg per kg per day of 
empiric scheduling to reach the therapeutic MPA AUC of 30-60mg.h/L. For current 
patient care, however, even at this moment measurement of MPA plasma concentrations 
can be of some help. In patients with lupus nephritis in whom MMF is used as induction 
therapy, one would expect to see a clinical response within a period of 3 months in most 
patients as elaborated later. If, after 3 months of therapy, in non-responders MPA AUC 
plasma concentrations are found to be low (say <30mg.h/L), then a dose increase may 
have favourable effects on the likelihood of reaching remission. However, if in the same 
patient MPA AUC is >60.0 mg/L already, then a further dose increase does not seem to 
be a good idea, as it may cause toxicity without additional benefit in efficacy. In such 
patients switching to another agent may be the preferred option. 
 GFR (Glomerular filtration rate) improved maximally within the first three 
months in this study followed by steady levels. Proteinuria continued to decline 
throughout the induction and maintenance phase, though the steepest decrease was in the 
initial three months. Albumin improvement was also most noticeable in the first three 
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months of treatment. About one third went into complete remission by 3 months and it 
progressively improved to 57% by 12 months. The complete remission rates improved 
through the maintenance phase to 88% at the end of two years. 
Partial remission was seen in 50% of the patients at three months. Cumulative remission 
which is the sum of complete and partial remission was seen in 94% at 3 months. In this 
study the remission rates were higher than that seen in similar studies described below in 
Asian population. Though this is encouraging in Asians where lupus nephritis is known 
to be severe; to categorically say whether the difference is due to exposure controlled 
MMF as opposed to fixed dose MMF will require randomized controlled trials. 
In a study by Chan et al for the Hong Kong Nephrology Study Group, with a 
median follow up period of 63 months, twenty-four (72.7%) patients in the MMF group 
and 23 (74.2%) in the Cyclophosphamide- Azathioprine group had complete remission. 
Partial remission was attained by 24.2 and 22.6% of patients in the two groups, 
respectively. They had used more stringent criteria with complete remission being 
defined as a value for urinary protein excretion that was less than 0.3g per 24 hours, with 
normal urinary sediment, a normal serum albumin concentration, and values for serum 
creatinine and creatinine clearance that were no more than 15 percent above the base-line 
value and also the outcomes were analyzed at the end of one year17. The treatment 
response was similar between the two groups (p= 0.878). The time to reach complete 
remission was 15.3 ± 8.9 wk in the MMF group and 19.7 ±11.2 wk in the CTX-AZA 
group (p=0.851). The incidence of complete remission was unrelated to baseline values 
of proteinuria, serum albumin, serum creatinine, anti-dsDNA antibodies, or C317. A study 
done by Gan et al in National University Hospital in Singapore among fifty patients in 
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2002 showed lower rates of response as compared to our study. It showed 44% percent 
were in complete remission, 26% in partial remission, 34% had relapsed nephritis, 4% 
had chronic renal failure and 12% progressed to ESRD and there were five deaths over 
three years118. This further corroborates the fact that Asians have severe lupus nephritis 
compared to their western counterparts.  
The median time to complete remission in this study is 11.1±1.3 months which is 
less than that reported by the Hong Kong Nephrology Study Group which used a fixed 
dose of MMF17. 
The earliest markers of remission were an improvement in GFR and proteinuria to 
subneprotic range in 2-3 months. Anti dsDNA took a median time of 4 months for 
normalization. Among the complement fractions, C4 was more specific than C3 taking a 
median time of 6 months for remission. Hence by 3-4 months we have an approximate 
knowldge of which patients are likely to respond to MPA therapy. 
 In this study neither leukopenia nor diarrhea had any correlation with the MPA 
AUC levels in this study. This contrasts to the study by Neumann et al where adverse 
events were clustered in patients with a high MPA trough exposure88. But since our 
numbers were small, no definite conclusions could be drawn. Infections were present in 7 
patients (13.5%) and again no strong correlation with MPA AUC could be demonstrated. 
 In this study, flares occurred in 4 patients. But majority of them had mild 
nephritic flares and all resolved without any modification of immunosuppression. There 
were no deaths. Comparing this to the Chan et al study with fixed dose MMF17; disease 
relapse affected 11 patients in the MMF group with 9 of them showing clinically 
significant renal involvement. 
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 In summary, Mycophenolate Mofetil is beneficial as both induction and 
maintenance therapy in lupus nephritis. Exposure controlled MPA does seem to have a 
role in follow up lupus nephritis patients. Since patients with autoimmune diseases are 
regularly treated with only one or two immunosuppressive drugs, an adequate MPA 
exposure may be even more important compared to renal transplant recipients receiving 
multiple immunosuppressive drugs. Also, in patients treated for autoimmune diseases 
MPA has highly variable pharmacokinetics, and dose is a poor predictor for MPA 
exposure. If in patients with autoimmune diseases MPA exposure can be shown to 
correlate with either efficacy or toxicity, then therapeutic drug monitoring could 
contribute to optimizing patient care. The least controversial area at present would be to 
help decide whether continuation of MMF therapy in a patient with suboptimal clinical 
and biochemical response is justified based on therapeutic drug levels. 
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LIMITATIONS 
 
 
 
 
1. This study was done on a prospective cohort of patients followed up for 
maximum of 1 year. Though this gives us relevant information regarding short 
term outcomes, it would be appropriate to follow up this cohort for longer periods 
to assess the impact on clinical, lab parameters and treatment on a long term. 
2. The heterogeneity of the treatment given, the genetic and geographic variations in 
the population studied would have been confounding variables in the assessment 
of outcomes.  
3. The present cohort study needs to be compared to a similar cohort of 
Cyclophosphamide treated patients to assess differences in outcomes, side effects 
and infections. 
4. In future a randomized controlled trial will need to be undertaken between 
patients receiving fixed dose MPA and exposure controlled MPA to assess the 
definite advantage of MPA AUC monitoring on clinical outcomes. 
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CONCLUSIONS 
 
 
1. Mycophenolate Mofetil is beneficial as both induction an maintenance therapy  
in lupus nephritis.  
2. With an empiric dosing schedule of 30mg/kg/day of Mycopheolate Mofetil 
(MMF),  55.8% of patients had 6 hour MPA AUC below the therapeutic range of 
30-60mg.h/L and 5.8% of patients had 6 hour MPA AUC above the therapeutic 
range. 
3.  After dose adjustment, the average dose of MMF required to attain therapeutic 
range was 35mg/kg/day in our study population. 
4. 57.6% had complete remission at 12 months in exposure controlled Mycophenolic 
Acid cohort and 50% had partial remission by 3 months. The complete remission 
rates improved through the maintenance phase to 88% at the end of two years. 
Partial remission was seen in 50% of the patients at three months. Cumulative 
remission which is the sum of complete and partial remission was seen in 94% at 
3 months. This is comparable to studies on Cyclophosphamide as induction 
therapy and Azathioprine as maintenance therapy. 
5. GFR was the earliest to improve with a median time of 2.6±0.85 months. 
6.  Proteinuria improved next at a median time of 3±1.3 months followed by Anti 
dsDNA at 4±0.3 months.C3 was the last to remit among the lab parameters at a 
median time of 12±2.4months. 
7. There were four flares with majority being mild nephritic flares that did not 
require any modification of immunosuppression. 
8.  Infectious episodes were present 17.3%  in the cohort.  
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                                                      ANNEXURE A 
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ANNEXURE B 
 
 
Duration of SLE symptoms (mts from diagnosis of LN) 
Duration of renal symptoms (mts from diagnosis of LN) 
ARA Criteria-Malar rash  Yes-1  /  No-0  Others 
  Discoid rash  Yes-1  /  No-0  Arthralgia  Yes-1  /  No-0 
Serositis  Yes-1  /  No-0  Alopecia  Yes-1  /  No-0 
  Oral ulcers  Yes-1  /  No-0  Raynauds  Yes-1  /  No-0 
Arthritis  Yes-1  /  No-0  Scleroderma Yes-1  /  No-0 
  Photosensitivity Yes-1  /  No-0  Palp purpura Yes-1  /  No-0 
  Hematological  Yes-1  /  No-0  Digital Gangr Yes-1  /  No-0 
  Renal   Yes-1  /  No-0  Thrombosis  Yes-1  /  No-0 
  ANA   Yes-1  /  No-0  Abortion Yes-1  /  No-0 
  Immunological  Yes-1  /  No-0  If yes, No. Trimester 
  Neurological  Yes-1  /  No-0 
Renal symptoms- 
Edema/Anasarca Yes-1  /  No-0 
Haematuria  Yes-1  /  No-0 
Oliguria  Yes-1  /  No-0 
N&V   Yes-1  /  No-0 
Pruritis  Yes-1  /  No-0 
Altered sensorium Yes-1  /  No-0 
Diabetes Yes-1  /  No-0 
Hypertension  No-0    /   1   /    2  /    3    /    4 
Prior Treatment Received    Duration/ No of pulses  mg/dl 
Steroids  Yes-1  /  No-0 
Inj Cyclo  Yes-1  /  No-0 
Oral Cyclo  Yes-1  /  No-0 
Aza   Yes-1  /  No-0 
MMF   Yes-1  /  No-0 
Cyclosporine  Yes-1  /  No-0 
MMF used for Induction Yes-1  /  No-0  Maintenance  Yes-1  /  No-0 
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Detail Visit 1 2 3 4 5 6 7 
Date        
Symptoms Improved – 2 / same -1/ worse-0        
BP        
No. of AntiHtn        
SLEDAI score        
Height (cm)        
Weight (kg)        
Hb        
WBC TC        
PLT        
Ur RBC        
Ur WBC        
S. Creat        
S. Urea        
S. Alb        
C3        
C4        
CH n-0 / low-1        
ANA +1/-0        
DsDNA +1/-0        
CANCA        
PANCA        
24HUP        
UP/UC        
DCT        
S.chol        
S.TG        
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Detail Visit 1 2 3 4 5 6 7 
LDL        
HDL        
LA +1/-0        
ACLA +1/-0        
REMISSION No -0 /Partial -1 
/Complete -2 
       
Relapse  Yes -1 / No – 0         
Flare – no-0 / nephritic -1 / nephrotic -2/ ARF -3 
/ CRF - 4  
       
Reason non compliance -1 / Inadequate level -2/ 
Infection - 3 / Side effects – 4 / Unknown -5 / Others- 
9   
       
Biopsy outside1/CMC-2/Nil-3        
Biopsy No.        
Biopsy Date        
Biopsy 
Class 
       
No. of glomeruli seen        
IF C3        
IF C4        
IF C1q        
IF IgA        
IF IgM        
IF IgG        
Interstitial Fibrosis        
Tubular Atrophy        
Crescents-
cellular1/fibrocellular2/fibrous3 
       
No of crescents        
Glomerulo 
Sclerosis No-0/ focal – 1/ diffuse – 2  
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Detail Visit 1 2 3 4 5 6 7 
Vasculitis No – 0 / Yes – 1        
Thrombotic microangiopathy        
Podocytopathy        
Activity index        
Chronicity index        
Prednisolone dose        
Pred Dose increased -1 / tapered -2/ same -3/ 
stopped -0 
       
IV methyl pred doses        
IV Cyclophos 
Monthly – 1 / Quarterly – 2 / Stop - 3 
       
Oral  Cyclophos Yes -1 / No – 0        
Aza Yes -1 / No – 0        
CsA Yes -1 / No – 0        
Keto Yes -1 / No – 0        
Tac Yes -1 / No – 0        
IVIG Yes -1/ No – 0        
ACEi/ARB Yes -1/No -0        
MMF No-0 / Cell – 1/ Myc -2/ Mofi-3 / 
Myfo-4 / Renf-5 / oth MMF – 8 / Oth MNA - 9 
       
Morn dose (mg)        
Eve dose (mg)        
6hr AUC         
Tmax        
Cmax        
C trough        
AUC low – 0 / normal – 1 / high - 2        
Why AUC not achieved?  cost – 1 / 
poor abs –2/ side effects-3/ Non compliance - 4 
       
S/E diarhea Yes -1/No  0        
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Detail Visit 1 2 3 4 5 6 7 
 Leucopenia Yes -1/No–0        
S/E Others 
 
       
Compliance Yes – 1 / No - 0        
MMF Brand change No-0 / Cell – 1/ 
Myc -2/ Mofi-3 / Myfo-4 / Renf-5 / oth MMF – 
8 / Oth MNA - 9 
       
Morn dose (mg)        
Eve dose (mg)        
6 hr AUC        
T max        
C max        
C trough        
MMF Drug Change No-0 / cost – 1 / 
poor abs –2/ side effects-3/ non response - 4 / flare – 5 
/ ARF – 6 / CRF – 7 /   improved-9 
       
MMF Drug Changed to IV Cyphos 1  
/ Oral Cyphos -2 / CsA -3/ Tac -4/ Aza  -5 
       
Non MMF drug change details         
Non MMF drug side effects        
Infections 
Bacteria isolated 
 
       
Viral 
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Detail Visit 1 2 3 4 5 6 7 
 
 
 
Fungal 
       
 
 
TB  
       
 
Protozoal 
 
       
 
 
Parasitic 
       
 
 
Gen Urinary 
       
 
 
RS 
       
 
GI system 
       
 
Sepsis 
       
 
CNS 
       
 
CVS 
       
Skin n S/C 
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Detail Visit 1 2 3 4 5 6 7 
 
 
Myositis 
       
Eye 
 
 
       
Others 
 
 
       
Lost to F/U  No – 0 / Yes – 1 
 
       
 
 
Death: in CMC - 1/ In hospital -2/ at home – 3 / no info - 9 
Cause of death-  
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